• Jiji

  • SHARE

A Japanese unit of British drugmaker AstraZeneca said Thursday that it has applied for approval from the health ministry to manufacture and sell its COVID-19 prevention and treatment drug in Japan.

AstraZeneca K.K., the Osaka-based unit, is seeking fast-track approval for the AZD7442 drug, known abroad as Evusheld.

In a time of both misinformation and too much information, quality journalism is more crucial than ever.
By subscribing, you can help us get the story right.

SUBSCRIBE NOW

PHOTO GALLERY (CLICK TO ENLARGE)